...
首页> 外文期刊>Breast cancer research and treatment. >Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
【24h】

Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.

机译:联合流式细胞术测定S期分数和DNA倍性是淋巴结阴性浸润性乳腺癌的独立预后因素:分析271例I和II期乳腺癌患者。

获取原文
获取原文并翻译 | 示例

摘要

Purpose. To assess the significance of S-phase fraction (SPF) and DNA ploidy evaluated by DNA flow cytometry as prognostic markers in stage I or II breast cancer.Patients and methods. A series of 271 patients, treated by surgery, radiotherapy +/- systemic therapy was analyzed (median follow up: 64 months). Standardized flow cytometry cell preparation from frozen samples and consensus rules for data interpretation were followed. Three SPF classes were defined on the basis of tertiles after adjustment for ploidy. Four groups were defined based on combinations of DNA ploidy (DIP: diploid; ANEUP: aneuploid) and SPF: DIP and low SPF (DL, n=37), DIP and medium or high SPF (DMH, n=76), ANEUP and low SPF (AL, n=24), ANEUP and medium or high SPF (AMH, n=68). Local control rate (LCR), disease-free survival (DFS), metastasis-free survival (MFS), and overall survival (OS) were correlated with DNA ploidy, SPF, DL to AMH groups, T and N stages, SBR grading, age, and hormonal status on univariate and multivariate analysis (Cox model).Results. On univariate analysis, DFS and LCR were higher for DIP tumours. High SPF values were associated with shorter DFS. LCR, MFS, DFS, and OS rates were significantly different with an increasingly poorer prognosis from DL to AMH. On multivariate analysis, groups DL to AMH, histological node involvement and T stage were independently associated with MFS, and DFS. In N(-) patients, DL to AMH remained independent for MFS and DFS. For SBR III tumours, MFS and OS were significantly different in DL to AMH groups. These results strongly support the use of combined evaluation of DNA ploidy and SPF as independent parameters in clinical trials for N(-) stage I and II breast cancer.
机译:目的。评估S期分数(SPF)和通过DNA流式细胞术评估的DNA倍性作为I或II期乳腺癌预后标志物的意义。患者和方法。分析了271例接受外科手术,放疗+/-全身治疗的患者(中位随访时间:64个月)。遵循标准化的流式细胞仪从冷冻样品制备细胞和数据解释的共识规则。调整了倍性后,根据三分位数定义了三个SPF类。根据DNA倍性(DIP:二倍体; ANEUP:非整倍体)和SPF:DIP和低SPF(DL,n = 37),DIP和中或高SPF(DMH,n = 76),ANEUP和低SPF(AL,n = 24),ANEUP和中或高SPF(AMH,n = 68)。局部控制率(LCR),无病生存期(DFS),无转移生存期(MFS)和总体生存期(OS)与DNA倍性,SPF,对AMH组的DL,T和N分期,SBR分级,单因素和多因素分析的年龄,激素状态(Cox模型)。在单因素分析中,DIP肿瘤的DFS和LCR较高。高SPF值与较短的DFS相关。 LDL,MFS,DFS和OS率显着不同,从DL到AMH的预后越来越差。在多变量分析中,DL至AMH组,组织学淋巴结转移和T期与MFS和DFS独立相关。在N(-)患者中,DL到AMH仍然独立于MFS和DFS。对于SBR III肿瘤,DL和AMH组的MFS和OS显着不同。这些结果强烈支持将DNA倍性和SPF的组合评估作为N(-)I和II期乳腺癌临床试验的独立参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号